Preferred Name | Myelodysplastic syndrome | |
Synonyms |
myelodysplastic syndromes MDS Myelodysplastic syndrome, NOS Myelodysplastic syndrome/neoplasm Dysmyelopoietic syndrome NCI CTEP SDC Myelodysplastic Syndrome Sub-Category Terminology Myelodysplastic neoplasm NCI CTEP Simple Disease Classification Myelodysplastic Syndrome Sub-Category Terminology Myelodysplasia Oligoblastic leukemia Preleukemia Smoldering leukemia Hematopoeitic - Myelodysplastic Syndrome (MDS) |
|
Definitions |
Myelodysplastic Syndrome is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology OR A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001) OR A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow. |
|
ID |
http://purl.obolibrary.org/obo/CCTO_000843 |
|
database_cross_reference |
UMLS:C0002894 UMLS:C3463824 UMLS:C0033027 NCIT:C3247 UMLS:C0026986 NCIT:C103128 UMLS:C0026985 NCI:CTCAE:10028533 UMLS:C2698684 UMLS:C3538995 |
|
definition |
Myelodysplastic Syndrome is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology OR A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001) OR A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow. |
|
has_exact_synonym |
myelodysplastic syndromes MDS Myelodysplastic syndrome, NOS Myelodysplastic syndrome/neoplasm Dysmyelopoietic syndrome NCI CTEP SDC Myelodysplastic Syndrome Sub-Category Terminology Myelodysplastic neoplasm NCI CTEP Simple Disease Classification Myelodysplastic Syndrome Sub-Category Terminology Myelodysplasia Oligoblastic leukemia Preleukemia Smoldering leukemia Hematopoeitic - Myelodysplastic Syndrome (MDS) |
|
has_obo_namespace |
cancer_care_treatment_outcome |
|
id |
CCTO:000843 |
|
label |
Myelodysplastic syndrome |
|
notation |
CCTO:000843 |
|
prefLabel |
Myelodysplastic syndrome |
|
schema |
CCTO:000843(time_t t0) = EVENT_STATE(CCTO:000843, t0) |
|
treeView | ||
XSTOO_rule |
CCTO:000843 implies CCTO:001122 CCTO:000843 implies CCTO:000049 |
|
subClassOf | ||
is_assessed_by |